Navigation Links
Smoking Women Less Receptive To IVF Treatment

Cigarette smoking affects female fertility is a long known fact. Menopause too sets in earlier in heavy smokers.//

Recently ,a study was conducted to compare IVF outcomes in smoking women. It was found that women who smoked less had a better chance of conceiving than women who smoked more than 10 cigarettes daily ,even with eggs donated by non-smokers.

Heavy smokers also tend to have multiple births according to the results obtained from the study. 60% of the heavy smokers had multiple births whereas only 31% of the nonheavy smokers had them.

It is now confirmed that smoking affects the womb and makes it less receptive to the embryo and reduces the chances for implantation and pregnancy.

Dr Sergio Soares, of the IVF Clinic in Lisbon and his team claim that their findings are the first to show that heavy smoking has an intense effect on the uterus. He added , “Even if fertilisation takes place, heavy smokers have less chance of achieving a successful pregnancy.”

The scientists compared the results of in-vitro fertilisation (IVF) treatments using eggs donated by non-smokers on 44 smokers who smoked more than 10 cigarettes a day and 785 women who smoked less.They were all married to non-smokers.

"The non-heavy smokers had a significantly higher pregnancy rate, with over half becoming pregnant (52.2 percent), compared with just over a third (34.1 percent) of the heavy smokers," Soares reported.


SR
'"/>




Page: 1

Related medicine news :

1. New hope on the Horizon for People Wishing to Quit Smoking
2. Cancers of Colon & Rectum linked to Cigarette Smoking
3. Smoking a greater risk than HIV? Yes say health experts!!!!
4. Kick Smoking with Nicotine Drink
5. Smoking spreads Cancer
6. Prescription Drug - Helps People Stop Smoking
7. Quit Smoking
8. Smoking can depreciate intellegence
9. Smoking Delays Pregnancy
10. Smoking Linked To Low Infant Birth Weight
11. GlaxoSmithKline To Cultivate Non-Smoking Environment
Post Your Comments:
Breaking Medicine Technology:Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4Elsevier Selects BrainTrack Directory as Supplier of College Data 2Elsevier Selects BrainTrack Directory as Supplier of College Data 3Elsevier Selects BrainTrack Directory as Supplier of College Data 4ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2Hoya Announces First Quarter Financial Results for FY2010 13321 1Hoya Announces First Quarter Financial Results for FY2010 13321 2Sports Icons Troy Aikman Clyde Drexler Mike Piazza Ivan Lendl and Dara Torres are Among the Elite Named 2009 Great Sports Legends 53448 1Sports Icons Troy Aikman Clyde Drexler Mike Piazza Ivan Lendl and Dara Torres are Among the Elite Named 2009 Great Sports Legends 53448 2Sports Icons Troy Aikman Clyde Drexler Mike Piazza Ivan Lendl and Dara Torres are Among the Elite Named 2009 Great Sports Legends 53448 3Sports Icons Troy Aikman Clyde Drexler Mike Piazza Ivan Lendl and Dara Torres are Among the Elite Named 2009 Great Sports Legends 53448 4Madzone Marketing LLC Taps TransMedia Group to Provide Publicity Lift to Knife and Forklift 28TM 29 53445 1Madzone Marketing LLC Taps TransMedia Group to Provide Publicity Lift to Knife and Forklift 28TM 29 53445 2
Other Medicine Technology:BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine 2Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology 2Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology 3Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology 4Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology 5Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology 6